


What is Claimed is:

1. A pharmaceutical composition useful for the treatment or prophylaxis of viral infections comprising tipranavir and
5 at least one antiviral active compound of formula (I)



wherein said Base is selected from the group consisting of thymine, cytosine, adenine, guanine, inosine, uracil, 5-ethyluracil and 2,6-diaminopurine, or a
10 pharmaceutically acceptable salt or prodrug thereof.

2. The pharmaceutical composition according to claim 1 wherein the compound of formula (I) is 3'-deoxy-3'-
15 fluorothymidine, or a pharmaceutically acceptable salt or prodrug thereof.
3. The pharmaceutical composition according to claim 1 wherein the compound of formula (I) is 2',3'-dideoxy-3'-
20 fluoroguanosine (FLG,) or a pharmaceutically acceptable salt or prodrug thereof.
4. The pharmaceutical composition according to claim 1 wherein the compound of formula (I) is 3'-deoxy-3'-
25 fluoro-5-O-[2-(L-valyloxy)-propionyl]guanosine, or a pharmaceutically acceptable salt thereof.

5. The pharmaceutical composition according to claim 1 wherein tipranavir and the compound of formula (I) are present in a synergistic ratio.
- 5 6. The pharmaceutical composition according to claim 1 wherein tipranavir and the compound of formula (I) are present in a ratio between about 1:250 to about 250:1.
7. The pharmaceutical composition according to claim 1
10 further comprising ritonavir.
8. The pharmaceutical composition according to claim 1 further comprising a further NRTI, or a pharmaceutically acceptable salt or prodrug thereof.
15
9. The pharmaceutical composition according to claim 1 with at least one pharmaceutically acceptable carrier.
10. The pharmaceutical composition according to claim 1
20 further comprising a non-nucleoside reverse transcriptase inhibitor (NNRTI).
11. The pharmaceutical composition according to claim 1 further comprising an entry inhibitor.
25
12. The pharmaceutical composition according to claim 1 further comprising an integrase inhibitor.
13. The pharmaceutical composition according to claim 10
30 further comprising an entry inhibitor.
14. The pharmaceutical composition according to claim 10 further comprising an integrase inhibitor.
- 35 15. The pharmaceutical composition according to claim 10 further comprising a further nucleoside reverse

transcriptase (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

5 16. The pharmaceutical composition according to claim 11 further comprising a further nucleoside reverse transcriptase (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.


10 17. The pharmaceutical composition according to claim 12 further comprising a further nucleoside reverse transcriptase (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

15 18. The pharmaceutical composition according to claim 13 further comprising a further nucleoside reverse transcriptase (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

20 19. The pharmaceutical composition according to claim 14 further comprising a further nucleoside reverse transcriptase (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

25 20. The pharmaceutical composition according to claim 1 comprising a further antiviral compound selected from the group consisting of: PA-457, KPC-2, HGTV-43, amprenavir, atazanavir, indinavir sulfate, fosamprenavir calcium, lopinavir, ritonavir, nelfinavir mesylate, saquinavir, AG-1776, AG-1859, DPC-681/684, GS224338, KNI-272, Nar-DG-
30 35, P(PL)-100, P-1946, R-944, RO-0334649, TMC-114, VX-385, and VX-478.

35 21. A method for the prophylaxis or treatment of a viral infection in a patient comprising administering tipranavir in combination or alternation with at least one antiviral active compound of formula (I)



I

wherein said Base is selected from the group consisting of
thymine, cytosine, adenine, guanine, inosine, uracil, 5-
5 ethyluracil and 2,6-diaminopurine, or a pharmaceutically
acceptable salt or prodrug thereof.

22. The method according to claim 21, wherein the compound of
formula (I) is 3'-deoxy-3'-fluorothymidine, or a
10 pharmaceutically acceptable salt or prodrug thereof.

23. The method according to claim 21, wherein the compound of
the formula (I) is 2',3'-dideoxy-3'-fluoroguanosine
(FLG), or a pharmaceutically acceptable salt or prodrug
15 thereof.


24. The method according to claim 21, wherein the compound of
the formula (I) is 3'-deoxy-3'-fluoro-5-O-[2-(L-
valyloxy)-propionyl]guanosine or a pharmaceutically
20 acceptable salt thereof.

25. The method according to claim 21, wherein the viral
infection is a human retroviral infection (HRV).

25 26. The method according to claim 25, wherein the human
retroviral infection is multiresistant human
immunodeficiency disease (HIV) infection.

27. The method according to claim 25, wherein perinatal transmission of the human retroviral (HRV) infection from mother to baby is prevented.
- 5 28. The method according to claim 21, wherein tipranavir and the compound of formula (I) are administered to the patient in combination or alternation in a synergistic ratio.
- 10 29. The method according to claim 21, wherein tipranavir and the compound of formula (I) are administered to the patient in combination or alternation in a ratio between about 1:250 to about 250:1.
- 15 30. The method according to claim 29, wherein tipranavir and the compound of formula (I) are administered to the patient in combination or alternation in a ratio between about 1:50 to about 50:1.
- 20 31. The method according to claim 21, wherein tipranavir is administered in combination with ritonavir and in combination or alternation with said compound of formula (I).
- 25 32. The method according to claim 21 further comprising administering in combination or alternation a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.
- 30 33. The method according to claim 21 wherein tipranavir is administered in combination with the compound of formula (I).
- 35 34. A kit of parts for the prophylaxis or treatment of a viral infection in a patient, comprising:

- (a) a first containment containing a pharmaceutical composition comprising tipranavir and at least one pharmaceutically acceptable carrier, and
- 5 (b) a second containment containing a pharmaceutical composition comprising an antiviral active compound of formula (I)



I

- 10 wherein Base is selected from the group consisting of thymine, cytosine, adenine, guanine, inosine, uracil, 5-ethyluracil and 2,6-diaminopurine, or a pharmaceutically acceptable salt or prodrug thereof, and at least one pharmaceutically acceptable carrier.
- 15 35. The kit of parts according to claim 34, wherein the compound of formula (I) is 3'-deoxy-3'-fluorothymidine, or a pharmaceutically acceptable salt or prodrug thereof.
- 20 36. The kit of parts according to claim 34, wherein the compound of the formula (I) is 2',3'-dideoxy-3'-fluoroguanosine (FLG), or a pharmaceutically acceptable salt or prodrug thereof.
- 25 37. The kit of parts according to claim 34, wherein the compound of the formula (I) is 3'-deoxy-3'-fluoro-5-O-[2-(L-valyloxy)-propionyl]guanosine, or a pharmaceutically acceptable salt thereof.

38. The kit of parts according to claim 34, further comprising a containment containing a pharmaceutical composition comprising ritonavir.

5 39. The kit of parts according to claim 34, further comprising a containment containing a pharmaceutical composition comprising a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

10

40. The kit of parts according to claim 34, further comprising a containment containing a pharmaceutical composition comprising an entry inhibitor.

15 41. The kit of parts according to claim 34, further comprising a containment containing a pharmaceutical composition comprising an integrase inhibitor.